Duchenne muscular dystrophy
Duchenne muscular dystrophy is an X-chromosome recessive allele disease that occurs primarily in muscle tissue and is common in children. That is, parents carry the gene but do not develop the disease, but the combination of the two can cause the disease in their offspring. It is mainly divided into two types: DMD (duchenne muscular dystrophy) and BMD (becker muscular dystrophy, BMD).
-
Site of disease:
muscle -
Infectious :
Not contagious -
Frequent population:
child -
Related symptoms:
Easy to fall Difficulty climbing stairs Muscle atrophy Intellectual development retardation
Related Drugs
EXONDYS 51- eteplirsen_injection
Indication: EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 EXONDYS 51 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 1.
Manufacturer:
Sarepta Therapeutics, Inc.
DEFLAZACORT- deflazacort_tablet
Indication: Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc. 's Emflaza registered Deflazacort tablets are a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1.
Manufacturer:
Upsher-Smith Laboratories, LLC
DEFLAZACORT- deflazacort_tablet
Indication: Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc. 's Emflaza registered Deflazacort tablets are a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1.
Manufacturer:
Upsher-Smith Laboratories, LLC
VYONDYS 53- golodirsen_injection
Indication: VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD [see Clinical Studies ( 14 VYONDYS 53 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD 1.
Manufacturer:
Sarepta Therapeutics, Inc.
AMONDYS 45- casimersen_injection
Indication: AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD [see Clinical Studies ( 14 AMONDYS 45 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD [see Clinical Studies ( 14 1.
Manufacturer:
Sarepta Therapeutics, Inc.